The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).
Enrique Grande
No relevant relationships to disclose
Carmen Guillen-Ponce
No relevant relationships to disclose
Jose Maria Vieitez de Prado
No relevant relationships to disclose
Margarita Reboredo
No relevant relationships to disclose
Gema Duran
No relevant relationships to disclose
Bartolomeu Massuti Sureda
No relevant relationships to disclose
Laura Layos
No relevant relationships to disclose
Antonia Salud
No relevant relationships to disclose
Esther Falco
No relevant relationships to disclose
Vicente Alonso
No relevant relationships to disclose
Pilar Garcia Alfonso
No relevant relationships to disclose
Maria Jose Ortiz
No relevant relationships to disclose
Javier Sastre
No relevant relationships to disclose
Fernando Rivera
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer
Javier Gallego
No relevant relationships to disclose
Luis Robles
No relevant relationships to disclose
Beatriz Gonzalez Astorga
No relevant relationships to disclose
Emma Dotor
No relevant relationships to disclose
Alfredo Carrato
No relevant relationships to disclose
Enrique Aranda
Consultant or Advisory Role - Merck; Roche